Boosting humoral and cellular immunity with enhanced STING activation by hierarchical mesoporous metal-organic framework adjuvants
Journal of Controlled Release · 2024
DOI: 10.1016/j.jconrel.2024.05.010 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Controlled Release, 2024. Verfasst von Chengjie Huang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Anesthesiology and Surgical Intensive Care Unit, Xinhua Hospital, School of Medicine and School of Biomedical Engineering, Shanghai Jia…. Hauptthemen laut MEDLINE: Immunity, Humoral. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 56 Literaturangaben.
Abstract (Originalsprache)
Vaccination is essential for preventing and controlling infectious diseases, along with reducing mortality. Developing safe and versatile adjuvants to enhance humoral and cellular immune responses to vaccines remains a key challenge in vaccine development. Here, we designed hierarchical mesoporous MOF-801 (HM801) using a Cocamidopropyl betaine (CAPB) and a Pluronics F127 in an aqueous phase system. Meanwhile, we synthesized a novel SARS-CoV-2 nanovaccine (R@M@HM801) with a high loading capacity for both the STING agonist (MSA-2) and the Delta receptor binding domain (Delta-RBD) antigen. R@M@HM801 enhanced MSA-2 and RBD utilization and effectively co-delivered MSA-2 and RBD antigens to antigen-presenting cells in the draining lymph nodes, thereby promoting the activation of both T and B cells. Lymphocyte single-cell analysis showed that R@M@HM801 stimulated robust CD11b+CD4+ T cells, CXCR5+CD4+ T follicular helper (Tfh), and durable CD4+CD44+CD62L-, CD8+CD44+CD62L- effector memory T cell (TEM) immune responses, and promoted the proliferative activation of CD26+ B cells in vivo. Meanwhile, R@M@HM801 induced stronger specific antibodies and neutralization of pseudovirus against Delta compared to the RBD + MAS-2 and RBD + MAS-2 + Alum vaccines. Our study demonstrated the efficacy of a hierarchical mesoporous HM801 and its potential immune activation mechanism in enhancing adaptive immune responses against viruses and other diseases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Anesthesiology and Surgical Intensive Care Unit, Xinhua Hospital, School of Medicine and School of Biomedical Engineering, Shanghai Jiao Tong University, Shanghai, China; State Key Laboratory of Systems Me…
- Shanghai Institute of Virology Shanghai Jiao Tong University School of Medicine 227 South Chongqing Road, Shanghai 200225, PR China. Electronic address: zhixiao@sjtu.edu.cn.
- Department of Cardiology, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200233, China.
- Department of Dermatology, Zhongshan Hospital of Fudan University, Shanghai 200032, China.
- School of Petrochemical Technology, Jilin Institute of Chemical Technology, Jilin 132022, China.
Zitieren
APA
Huang, C., Zhi, X., Ye, T., Wang, X., Li, K., Li, Y., Zhang, Q., Jiang, L., & Ding, X. (2024). Boosting humoral and cellular immunity with enhanced STING activation by hierarchical mesoporous metal-organic framework adjuvants. Journal of Controlled Release. https://doi.org/10.1016/j.jconrel.2024.05.010
Vancouver
Huang C, Zhi X, Ye T, Wang X, Li K, Li Y, et al. Boosting humoral and cellular immunity with enhanced STING activation by hierarchical mesoporous metal-organic framework adjuvants. Journal of Controlled Release. 2024. doi:10.1016/j.jconrel.2024.05.010
BibTeX
@article{Huang2024,
author = {Huang, Chengjie and Zhi, Xiao and Ye, Tianbao and Wang, Xiuyuan and Li, Ke and Li, Yiyang and Zhang, Qiang and Jiang, Lai and Ding, Xianting},
title = {Boosting humoral and cellular immunity with enhanced STING activation by hierarchical mesoporous metal-organic framework adjuvants},
journal = {Journal of Controlled Release},
year = {2024},
doi = {10.1016/j.jconrel.2024.05.010}
}
EUVIMED